@article{Athanasakis2020-nj,
title = {A cost of illness analysis of hepatocellular carcinoma for the
Greek healthcare setting},
author = {Kostas Athanasakis and Fani Pliarchopoulou and Vasiliki Naoum and Christos Psarrakis and Nikolaos Tziolos and Theodoros Marantos and Christina Damoulari and Athina Chounta},
year = {2020},
date = {2020-01-01},
journal = {Gastroenterol Hepatol Bed Bench},
volume = {13},
number = {3},
pages = {219--222},
abstract = {AIM: To estimate the cost per patient for hepatocellular
carcinoma in Greece, a setting that is currently facing financial
constraints. BACKGROUND: Hepatocellular carcinoma patient
management strategies are associated with significant costs.
Despite this, patient level data on healthcare resource use and
cost-of-illness analyses of hepatocellular carcinoma remain
rather scarce in the international literature. METHODS: 123
patients diagnosed with hepatocellular carcinoma and followed in
a specialised clinic of a tertiary hospital in Greece formed the
basis of the analysis. Detailed resource use data were derived
from the medical records of each patient. Data were recorded from
the first encounter of the patient with the facility until a
fatal endpoint or until the last day of follow up. Patients that
were lost to follow-up were excluded from the analysis.
Calculations follow a third-party payer perspective, according to
official prices and tariffs. RESULTS: The average cost per
patient was estimated at 12,119.1 Euros (SD: 14,670.3) (21,375.1
PPP USD) for the average follow-up period and 10,241.5 Euros
(18,063.5 PPP USD) per year. Median costs per month of follow-up
according to underlying disease were 1,218.1, 1,376.8, 1,521.3
and 686.9 Euros (2,148.4, 2,428.3, 2,683.2 and 1,211.5 PPP USD)
for patients with alcoholic steatohepatitis, hepatitis B,
hepatitis C and non-alcoholic fatty liver disease, respectively.
CONCLUSION: Hepatocellular carcinoma represents a heavy toll,
both from the clinical as well as from the economic perspective,
especially for a setting in ``dire straits''. Interventions
towards reducing the incidence and, subsequently, the cost of HCC
are imperative.},
keywords = {Cost-of-illness; Economic evaluation; Hepatocellular cancer},
pubstate = {published},
tppubtype = {article}
}
AIM: To estimate the cost per patient for hepatocellular
carcinoma in Greece, a setting that is currently facing financial
constraints. BACKGROUND: Hepatocellular carcinoma patient
management strategies are associated with significant costs.
Despite this, patient level data on healthcare resource use and
cost-of-illness analyses of hepatocellular carcinoma remain
rather scarce in the international literature. METHODS: 123
patients diagnosed with hepatocellular carcinoma and followed in
a specialised clinic of a tertiary hospital in Greece formed the
basis of the analysis. Detailed resource use data were derived
from the medical records of each patient. Data were recorded from
the first encounter of the patient with the facility until a
fatal endpoint or until the last day of follow up. Patients that
were lost to follow-up were excluded from the analysis.
Calculations follow a third-party payer perspective, according to
official prices and tariffs. RESULTS: The average cost per
patient was estimated at 12,119.1 Euros (SD: 14,670.3) (21,375.1
PPP USD) for the average follow-up period and 10,241.5 Euros
(18,063.5 PPP USD) per year. Median costs per month of follow-up
according to underlying disease were 1,218.1, 1,376.8, 1,521.3
and 686.9 Euros (2,148.4, 2,428.3, 2,683.2 and 1,211.5 PPP USD)
for patients with alcoholic steatohepatitis, hepatitis B,
hepatitis C and non-alcoholic fatty liver disease, respectively.
CONCLUSION: Hepatocellular carcinoma represents a heavy toll,
both from the clinical as well as from the economic perspective,
especially for a setting in ``dire straits''. Interventions
towards reducing the incidence and, subsequently, the cost of HCC
are imperative.